Tosedostat CAS: 238750-77-1

CAS NO: 238750-77-1
Chemical Name: Tosedostat
Molecular Formula: C21H30N2O6
Formula Weight: 406.47
CAS No.: 238750-77-1
Description Review

Tosedostat is a promising new drug used to treat acute myeloid leukemia (AML) and other cancerous conditions. This compound is a synthetic aminopeptidase inhibitor that is used to target the cancer cells by selectively working on the caseinolytic peptidase-anabolic metabolism by it prevents the degradation of anabolic peptides contributing to survival and aggressive growth of leukemic cells.

Chemical name:

The chemical name of Tosedostat is N-((1S)-1-(hydroxyacetyl)-4-methylpiperidin-4-yl)-N'-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-6-yl)urea.

Molecular formula:

The chemical formula of Tosedostat is C18H26N6O4

Formula weight:

The formula weight of Tosedostat is 382.44 g/mol.


The CAS No of Tosedostat is 238750-77-1.


Top 10 keywords for Tosedostat on Google include clinical trials, leukemia, mechanism of action, pharmacology, cancer, drug resistance, survival rate, targeted therapy, and pharmacokinetics.


The synonyms for Tosedostat include CHR-2797, CHR2797, and N-((1S)-1-(hydroxyacetyl)-4-methylpiperidin-4-yl)-N'-(6-(4-methoxy-1H-pyrrolo[2,3-d]pyrimidin-7-yl)pyridin-2-yl)urea.

Health benefits of this product:

Tosedostat is used primarily in the treatment of acute myeloid leukemia (AML) and other cancer-related conditions. AML is one of the most common types of leukemia in adults and children. It can cause symptoms such as fever, fatigue, weight loss, and swollen lymph nodes. Tosedostat works by selectively inhibiting the actions of aminopeptidase enzymes in cancer cells, which help to regulate cellular metabolism and promote cancer cell growth. As a result, Tosedostat prevents the growth and spread of cancer cells and may also enhance the effectiveness of existing cancer therapies.

Potential effects:

Tosedostat can have several potential effects on the body, depending on the dosage and frequency of use. Some of the key effects of this drug include the following:

  • Tosedostat prevents the degradation of anabolic peptides contributing to survival and aggressive growth of leukemic cells.
  • Inhibits the action of key aminopeptidase enzymes that promote cancer cell growth.
  • Enhances the effectiveness of existing cancer therapies.
  • May improve the survival rate of patients with AML and other leukemias.

Product mechanism:

As previously mentioned, Tosedostat works primarily by selectively inhibiting aminopeptidase enzymes in cancer cells. These enzymes play a key role in cellular metabolism, regulating the availability of amino acids and other nutrients required for cell growth and replication. Cancer cells often overexpress these enzymes, leading to increased metabolic activity and growth. By inhibiting aminopeptidases, Tosedostat disrupts the metabolic pathways that promote cancer cell growth and proliferation, effectively slowing or stopping tumor growth.


Tosedostat is generally considered to be safe and well-tolerated when taken as directed. However, like all drugs, it may cause certain side effects in some patients. It is important to talk to your doctor about any potential side effects you may experience, as well as any other health concerns you may have. Tosedostat can also interact with other medications, supplements, and foods, so it is important to discuss all of these factors with your doctor before starting treatment.

Side effects:

Common side effects of Tosedostat may include nausea, vomiting, diarrhea, abdominal pain, fatigue, weakness, headache, and bone pain. Some patients may also experience symptoms such as anemia, thrombocytopenia, lymphopenia, and neutropenia, which can occur as a result of decreased blood cell production. In rare cases, Tosedostat may cause more serious side effects such as liver or kidney damage, allergic reactions, or lung problems. It is important to seek medical attention immediately if you experience any of these symptoms.

Dosing information:

The recommended dose of Tosedostat will vary depending on the specific condition being treated, patient age and overall health, and other factors. It is important to follow your doctor's instructions carefully when taking this medication, and to avoid changing your dosage or stopping treatment without first consulting your healthcare provider. To help ensure the safety and effectiveness of Tosedostat treatment, it is important to attend regular follow-up appointments with your doctor and to undergo regular blood tests to monitor your response to the medication.


Tosedostat is a promising new drug for the treatment of acute myeloid leukemia (AML) and other cancerous conditions. This synthetic aminopeptidase inhibitor works by selectively targeting the metabolic pathways that promote cancer cell growth and proliferation, effectively slowing or stopping tumor growth. While Tosedostat is generally considered to be safe and well-tolerated, it can cause certain side effects and may interact with other medications and supplements. If you are considering Tosedostat as a treatment option for cancer or another condition, it is important to discuss potential benefits, risks, and alternative treatments with your doctor.


Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
Message Us